Publications

2018

Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamò A, et al. Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer Res. 2018;78(13):3413-3420.
Reina-Campos M, Shelton PM, Diaz-Meco MT, Moscat J. Metabolic reprogramming of the tumor microenvironment by p62 and its partners. Biochim Biophys Acta Rev Cancer. 2018;1870(1):88-95.
Patel N, Cricco-Lizza E, Kasabwala K, Xu C, Robinson BD, Khani F, et al. The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy. Eur Urol Oncol. 2018;1(4):263-267.
Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, et al. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Adv. 2018;2(24):3618-3626.
Stopsack KH, Gonzalez-Feliciano AG, Peisch SF, Downer MK, Gage RA, Finn S, et al. A Prospective Study of Aspirin Use and Prostate Cancer Risk by Status. Cancer Epidemiol Biomarkers Prev. 2018;27(10):1231-1233.
Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, et al. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018;39(12):1431-1437.
Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499-503.
Sweeney J, Rao R, Margolskee E, Goyal A, Heymann JJ, Siddiqui MT. Immunohistochemical staining for S100P, SMAD4, and IMP3 on cell block preparations is sensitive and highly specific for pancreatic ductal adenocarcinoma. J Am Soc Cytopathol. 2018;7(6):318-323.
Ellis L, Loda M. LSD1: A single target to combat lineage plasticity in lethal prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4530-4531.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700